Innoforce is off to the races at its new site in the city of Hangzhou. It plans to bring on over 300 employees at the site by the end of next year.
The Chinese CDMO announced last week that it has started manufacturing at the new facility, which was built to offer process development and manufacturing operations for RNA, plasmid DNA, viral vectors and other cell therapeutics. It will also serve as Innoforce’s corporate HQ. Innoforce is off to the races at its new site in the city of Hangzhou, China.
InnoForce Group is a group of companies providing comprehensive IT services and modern solutions to public organizations and private companies.
The company said it’s investing more than $200 million in the 550,000-square-foot manufacturing base for advanced therapies. The GMP manufacturing facility features space for producing plasmids with three 30-liter bioreactors. GMP is a system for ensuring that products are consistently produced and controlled according to quality standards.
For viral vector manufacturing, Innoforce also has 200- and 500-liter bioreactors at its disposal, along with eight suites to make cell therapies. The site also includes several labs and warehouse spaces. Innoforce plans to bring on over 300 employees at the site by the end of next year.
“Building on existing capabilities, including our outstanding workforce, scale, and modern technology platforms, we are well-positioned to help clients overcome common pain points and bring revolutionary advanced therapies to market. We believe our platform can support clients to reduce cycle times, increase efficiency, and ensure supply reliability that meets international regulators’ requirements,” Min Zhu, SVP of CDMO operations at Innoforce, said in a statement.
Innoforce has been hard at work on the facility. Just last year, it reeled in another $96 million which went straight to construction, with blueprints for a new monoclonal antibody manufacturing facility coming through a partnership with Thermo Fisher Scientific.
The partnership with Thermo Fisher was inked in 2020, which saw the Massachusetts-based manufacturer agree with Innoforce to establish a new pharma services facility in Hangzhou for biologics and sterile drug manufacturing.
Originally published at END POINTS VIEW